NRG Energy’s $0.34B Volume Surges 39.77% to Rank 346th as Shares Edge Up 0.07%

On September 8, 2025, , . , ranking 346th in trading volume among listed equities.

NRG Therapeutics, a neuroscience firm targeting in neurodegenerative diseases, . The round included participation from British Business Bank, M Ventures, Novartis Venture Fund, and existing investors Omega Funds and Brandon Capital. Proceeds will advance clinical proof of concept for NRG5051, its lead oral mPTP inhibitor candidate, in ALS/MND and generate Parkinson’s data via a Phase 1b trial. The financing also expands board representation, with new members joining from key investors.

The company’s platform focuses on inhibiting mitochondrial permeability transition pores (mPTP), a mechanism linked to neuronal death in conditions like Parkinson’s and ALS. NRG5051, which has completed IND-enabling studies, . Investors highlighted the unmet medical need in , where current treatments offer only symptomatic relief. The funding underscores growing interest in therapies targeting , a common pathological pathway in aging-related disorders.

Back-test parameters require clarification on stock universe definitions, portfolio weighting methods, transaction cost assumptions, and risk controls. Default settings—such as U.S. common stocks, equal-weight allocation, and no additional risk measures—can be applied if unspecified. Corporate actions and liquidity constraints will need further input to refine the model.